Chymase-dependent angiotensin II formation in human blood vessels

Journal of Human Hypertension

Volumn 14, Issue 6, 2000, Pages 373-376

  Chester, Adrian H ^a   Borland, J A A ^a  

^a HAREFIELD HOSPITAL   (United Kingdom)

Author keywords

Angiotensin II; Chymase

Indexed keywords

ANGIOTENSIN; BRADYKININ; CATHEPSIN G; CHYMASE; DIPEPTIDYL CARBOXYPEPTIDASE; KALLIKREIN; NAFAMSTAT; NITRIC OXIDE; SUPEROXIDE; TRANILAST;

BLOOD VESSEL; CONFERENCE PAPER; ENZYME ACTIVITY; ENZYME LOCALIZATION; PERIPHERAL VASCULAR DISEASE; RESTENOSIS;

EID: 0033932368     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jhh.1001022     Document Type: Conference Paper

References (53)

1. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991; 325: 293-302.
2. Osterrieder W et al. Role of angiotensin II in injury-induced neointima formation in rats. Hypertension 1991; 18 (Suppl 4): II60-II64.
3. Cohn JN et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure [see comments]. N Engl J Med 1991; 325: 303-310.
4. Dahlof B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. Am J Hypertens 1992; 5: 95-110.
5. Azizi M et al. Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives. Circulation 1995; 92: 825-834.
6. Mento PF, Wilkes BM. Plasma angiotensins and blood pressure during converting enzyme inhibition. Hypertension 1987; 9: III42-III48.
7. Urabe Y et al. Beneficial effects of a serine protease inhibitor in peripheral vascular disease. Am J Cardiol 1993; 72: 218-222.
8. Miura S et al. Angiotensin II formation by an alternative pathway during exercise in humans. J Hypertens 1994; 12: 1177-1181.
9. Urata H et al. Angiotensin II-forming pathways in normal and failing human hearts. Circ Res 1990; 66: 883-890.
10. Lindberg BF et al. Angiotensin I is converted to angiotensin II by a serine protease in human detrusor smooth muscle. Am J Physiol 1994; 266: R1861-R1867.
11. Borland JA, Chester AH, Morrison KA, Yacoub MH. Alternative pathways of angiotensin II production in the human saphenous vein. Br J Pharmacol 1998; 125: 423-428.
12. Voors AA et al. Dual pathway for angiotensin II formation in human internal mammary arteries. Br J Pharmacol 1998; 125: 1028-1032.
13. Arakawa K, Yuki M, Ikeda M. Chemical identity of tryptensin with angiotensin. Biochem J 1980; 187: 647-653.
14. Tonnesen MG, Klempner MS, Austen KF, Wintroub BU. Identification of a human neutrophil angiotension II-generating protease as cathepsin G. J Clin Invest 1982; 69: 25-30.
15. Garcia R, Schiffrin EL, Thibault G, Genest J. Effects of tonin, an angiotensin II-forming enzyme, on vascular smooth muscle in the normal rabbit. Hypertension 1981; 3: I101-I106.
16. Arakawa K, Maruta H. Ability of kallikrein to generate angiotensin II-like pressor substance and a proposed 'kinin-tensin enzyme system'. Nature 1980; 288: 705-706.
17. Yamamoto K, Chappell MC, Brosnihan KB, Ferrario CM. In vivo metabolism of angiotensin I by neutral endopoptidase (EC 3.4.24.11) in spontaneously hypertensive rats. Hypertension 1992; 19: 692-696.
18. Urata H et al. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart [published erratum appears in J Biol Chem 1991; 25; 266: 12114]. J Biol Chem 1990; 265: 22348-22357.
19. Okunishi H, Miyazaki M, Okamura T, Toda N. Different distribution of two types of angiotensin II-generating enzymes in the aortic wall. Biochem Biophys Res Commun 1987; 149: 1186-1192.
20. Lindberg BF, Gyllstedt E, Anderson KE. Conversion of angiotensin I to angiotensin II by chymase activity in human pulmonary membranes. Peptides 1997; 18: 847-853.
21. Wolny A et al. Functional and biochemical analysis of angiotensin II-forming pathways in the human heart. Circ Res 1997; 80: 219-227.
22. Borland JAA et al. Localisation and function of the renin angiotensin system in the human radial artery versus the internal thoracic artery. Circulation (Suppl) 1998; 98: 606.
23. Schwartz LB et al. Quantitation of histamine, tryptase, and chymase in dispersed human T and TC mast cells. J Immunol 1987; 138: 2611-2615.
24. Takai S et al. Characterization of chymase from human vascular tissues. Clin Chim Acta 1997; 265: 13-20.
25. Urata H, Strobel F, Ganten D. Widespread tissue distribution of human chymase. J Hypertens Suppl 1994; 12: S17-S22.
26. Snyder RA, Wintroub BU. Inhibition of angiotensin-converting enzyme by des-Leu 10-angiotensin I: a potential mechanism of endogenous angiotensin-converting enzyme regulation. Biochim Biophys Acta 1986; 871: 1-5.
27. Kokkonen JO, Saarinen J, Kovanen PT. Regulation of local angiotensin II formation in the human heart in the presence of interstitial fluid. Inhibition of chymase by protease inhibitors of interstitial fluid and of angiotensin-converting enzyme by Ang-(1-9) formed by heart carboxypeptidase A-like activity. Circulation 1997; 95: 1455-1463.
28. Welches WR, Brosnihan KB, Ferrario CM. A comparison of the properties and enzymatic activities of three angiotensin processing enzymes: angiotensin converting enzyme, prolyl endopeptidase and neutral endopeptidase 24.11. Life Sci 1993; 52: 1461-1480.
29. Strawn WB, Ferrario CM, Tallant EA. Angiotensin-(1-7) reduces smooth muscle growth after vascular injury. Hypertension 1999; 33: 207-211.
30. Freeman EJ, Chisolm GM, Ferrario CM, Tallant EA. Angiotensin-(1-7) inhibits vascular smooth muscle cell growth. Hypertension 1996; 28: 104-108.
31. Ferrario CM, Iyer SN. Angiotensin-(1-7): a bioactive fragment of the renin-angiotensin system. Regul Pept 1998; 78: 13-18.
32. Grise C, Boucher R, Thibault G, Genest J. Formation of angiotensin II by tonin from partially purified human angiotensinogen. Can J Biochem 1981; 59: 250-255.
33. Thibault G, Genest J. Tonin, an esteroprotease from rat submaxillary glands. Biochim Biophys Acta 1981; 660: 23-29.
34. Ikeda M, Sasaguri M, Maruta H, Arakawa K. Formation of angiotensin II by tonin-inhibitor complex. Hypertension 1988; 11: 63-70.
35. Okunishi H et al. Marked species-difference in the vascular angiotensin II-forming pathways: humans versus rodents. Jpn J Pharmacol 1993; 62: 207-210.
36. Maassenvandenbrink A, de Vries R, Saxena PR, Danser AHJ. ACE not chymase, generates angiotensin II (AII) in close proximity to the ATI receptor in the human coronary artery. Circulation (Suppl) 1998; 98: 606.
37. Martin JF, Booth RF, Moncada S. Arterial wall hypoxia following hyperfusion through the vasa vasorum is an initial lesion in atherosclerosis. Eur Clin Invest 1990; 20: 588-592.
38. Booth RF et al. Rapid development of atherosclerotic lesions in the rabbit carotid artery induced by perivascular manipulation [see comments]. Atherosclerosis 1989; 76: 257-268.
39. Barker SG et al. Arterial intimai hyperplasia after occlusion of the adventitial vasa vasorum in the pig. Arterioscler Thromb 1993; 13: 70-77.
40. Diet F et al. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation 1996; 94: 2756-2767.
41. Jeziorska M, McCollum C, Woolley DE. Mast cell distribution, activation, and phenotype in atherosclerotic lesions of human carotid arteries [published erratum appears in J Pathol 1997; 183: 248]. J Pathol 1997; 182: 115-122.
42. Zisman LS et al. Angiotensin II formation in the intact human heart. Predominance of the angiotensin-converting enzyme pathway. J Clin Invest 1995; 95: 1490-1498.
43. Zisman LS et al. Angiotensin II formation in the intact human heart. Predominance of the angiotensin-converting enzyme pathway. J Clin Invest 1995; 96: 1490-1498.
44. Borland JA et al. Differential action of angiotensin II and activity of angiotensin-converting enzyme in human bypass grafts. J Thorac Cardiovasc Surg 1998; 116: 206-212.
45. Kovanen PT. Chymase-containing mast cells in human arterial intima: implications for atherosclerotic disease. Heart Vessels 1997; 12 (Suppl): 125-127.
46. Shiota N et al. Tranilast suppresses vascular chymase expression and neointima formation in balloon-injured dog carotid artery. Circulation 1999; 99: 1084-1090.
47. Takai S et al. Induction of chymase that forms angiotensin II in the monkey atherosclerotic aorta. FEBS Lett 1997; 412: 86-90.
48. Faxon DP. Effect of high dose angiotensin-converting enzyme inhibition on restenosis: final results of the MARCATOR Study, a multicenter, double-blind, placebo-controlled trial of cilazapril. The Multicenter American Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR) Study Group. J Am Coll Cardiol 1995; 25: 362-369.
49. Mancini GBJ et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) study. Circulation 1996; 94: 258-265.
50. Rajagopalan S, Harrison DG. Reversing endothelial dysfunction with ACE inhibitors. A new TREND? Circulation 1996; 94: 240-243.
51. Benzie IF, Tomlinson B. Antioxidant power of angiotensin-converting enzyme inhibitors in vitro. Br J Clin Pharmacol 1998; 45: 168-169.
52. Chopra M et al. Antioxidant effects of angiotensin-converting enzyme (ACE) inhibitors: free radical and oxidant scavenging are sulfhydryl dependent, but lipid peroxidation is inhibited by both sulfhydryl- and nonsulfhydryl-containing ACE inhibitors. J Cardiovasc Pharmacol 1992; 19: 330-340.
53. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994; 74: 1141-1148.